ETF Managers Group’s CorMedix CRMD Stock Holding History

ETF Managers Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$56.7K	Buy	13,706 +3,414	+33%	+$14K	﹤0.01%	659
2022 Q4	$43.4K	Sell	10,292 -1,868	-15%	-$6.61K	﹤0.01%	501
2022 Q3	$34K	Sell	12,160 -200	-2%	-$832	﹤0.01%	676
2022 Q2	$44K	Buy	12,360 +807	+7%	+$3K	﹤0.01%	716
2022 Q1	$68K	Buy	11,553 +43	+0.4%	+$197	﹤0.01%	648
2021 Q4	$54K	Sell	11,510 -2,660	-19%	-$13.2K	﹤0.01%	665
2021 Q3	$66K	Buy	14,170 +2,935	+26%	+$17.1K	﹤0.01%	647
2021 Q2	$80K	Buy	11,235 +1,392	+14%	+$11.1K	﹤0.01%	629
2021 Q1	$88K	Sell	9,843 -5,786	-37%	-$60.9K	﹤0.01%	643
2020 Q4	$115K	Sell	15,629 -1,893	-11%	-$12.9K	﹤0.01%	594
2020 Q3	$103K	Buy	17,522 +9,812	+127%	+$49.3K	﹤0.01%	600
2020 Q2	$48K	Buy	+7,710	New	+$35.7K	﹤0.01%	591

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

ETF Managers Group's CRMD Position: Q1 2023 in Review

ETF Managers Group increased its CorMedix (CRMD) stake by 33% in Q1 2023, buying an estimated $14K and bringing the position to 13,706 shares worth $56.7K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

ETF Managers Group first reported a position in CRMD in Q2 2020 and has held it in 12 quarters since. The position peaked at $115K in Q4 2020. 65 funds tracked by Wall St. Rank hold CRMD as of Q1 2023.

ETF Managers Group held 13,706 shares of CorMedix worth $56.7K as of Q1 2023.
ETF Managers Group bought 3,414 CorMedix shares in Q1 2023, an estimated $14K.
CorMedix made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #659 holding.
ETF Managers Group first reported a position in CorMedix in Q2 2020 and has held it in 12 quarters since.
ETF Managers Group's CorMedix position peaked at $115K in Q4 2020.
65 funds tracked by Wall St. Rank held CorMedix as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.